Related Articles: Merck's Keytruda held back by docs who don't want to wait for diagnostics Bristol's Opdivo - Yervoy combo ups response rates in first -
line lung cancer patients Roche's Tecentriq bursts onto immuno - oncology scene, with Merck and BMS in its sights Bristol - Myers» new Opdivo ad touts biomarker advantage over Merck's Keytruda Merck's Keytruda lines up its survival data for stepped - up battle with BMS» Opdivo
Not exact matches
That leaves Merck largely free of competitors in the near - term in its quest to become a go - to, first -
line option for
lung cancer patients in combination with chemotherapy (Merck recently surprised investors with an early FDA filing for that combination).
Along the same
lines, Daniel Sessler, an anesthesiologist at Cleveland Clinic in Ohio, is leading two randomized trials looking at whether nerve blocks added to general anesthesia reduce metastases in
patients undergoing surgery to remove either breast or
lung cancer.
Dr. Glen Weiss, M.D., M.B.A., is the first author of the study abstract: Phase Ib / II Study of Pembrolizumab plus Chemotherapy in Advanced
Cancer: Results of lung cancer patients receiving (at least) 1 prior line of th
Cancer: Results of
lung cancer patients receiving (at least) 1 prior line of th
cancer patients receiving (at least) 1 prior
line of therapy.
They found out that TiY is capable of distinguishing TICs from non-TICs in various human
lung cancer cell
lines and
patient - derived
lung tumors.
Nana - Sinkam and his colleagues examined
lung - tumor samples from 81
patients with stage - 1 nonsmall - cell
lung cancer and tumor - cell
lines.
Pembrolizumab is set to become a new option for first
line treatment of
patients with advanced
lung cancer and high PD - L1 expression, according to the results of the phase III KEYNOTE - 024 trial presented at the ESMO 2016 Congress in Copenhagen and published in the New England Journal of Medicine.
«First -
line immunotherapy treatment can improve survival for subset of
lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV
lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»
«
Patients with non-small cell
lung cancer (NSCLC) should receive front
line therapy with the anaplastic lymphoma kinase (ALK) inhibitor crizotinib,» said lead author Professor Giorgio Scagliotti, head of the Department of Oncology, University of Turin, Italy.
On October 2, 2015, the FDA approved the immunotherapy drug pembrolizumab (Keytruda ®), made by Merck, as second -
line treatment for
patients with
lung cancer, the leading cause of
cancer - related death in the U.S. and the world.
$ 1.8 M Supports
Cancer Drug Discovery on Commonly Mutated Gene New Brunswick Patch — April 5, 2016 Behavioral Scientist Shares Insights about FDA's Proposed Rule on Banning Tanning Bed Use among Minors News-Medical.net - March 19, 2016 Intervention Program Reduces Caregiver Distress during Hospitalization of Pediatric Stem Cell Transplant
Patients News-Medical.net - March 9, 2016 Exploring Genomic Pathways in the Development of Ovarian
Cancer GMNews.com - March 2, 2016 Differences in Type of Small Protein may further Elucidate
Lung Cancer Risk in African Americans ScienceDaily.com - March 2, 2016 Study Looks at Post-Treatment Resources for Prostate
Cancer Patients Transitioning to Survivorship News-Medical.net - February 11, 2016 Drawing the
Line on Tanning Bed Use by Teens ScienceDaily.com - December 21, 2015 What Rutgers Study Uncovered about E-Cigarette Use NJBiz.com - December 9, 2015 Identification of Barrier that Prevents Progression of Benign Kidney Tumors to Malignant Disease MedicalNewsToday.com - November, 24, 2015 What is the Color of the
Lung Cancer Ribbon?
With the recent announcement that a first -
line immunotherapy trial for non-small cell
lung cancer (NSCLC) is positive for survival improvement, I can see the standard of care for
lung cancer patients radically changing over the next few years.
Researchers tested the effects of CBD, THC, and an endocannabinoid analogue called methanandamide on two
lung cancer cell
lines, A549 and H460, along with cells from a
lung cancer patient.
This drug is indicated in combination with Cisplatin (a chemotherapeutic drug) for the first -
line treatment of
patients with inoperable, locally advanced, or metastatic non-small cell
lung cancer.
Mesothelioma is a form of
cancer affecting the
linings of certain internal body organs of a
patient, such as the
lungs, heart and chest cavity, and has been linked to asbestos exposure earlier in the life of the
patient.